Ascendis Pharma A/S
Organization details
- Legal name
- Ascendis Pharma A/S
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Denmark
- Headquarters city
- Hellerup
- Headquarters country
- Denmark
- Fiscal year end
- December
- Ticker symbol
- ASND
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001612042
- Wikidata ID
- Q104479983
Board of directors
-
Albert Cha · DirectorSince 2026
-
Jan Moller Mikkelsen · DirectorSince 2026
- Since 2026
-
Lars Holtug · DirectorSince 2026
-
Lisa Morrison · DirectorSince 2026
-
Siham Imani · DirectorSince 2026
-
William Fairey · DirectorSince 2026
Board connections
3 of this board's directors also sit on 7 other boards. 7 are in the same sector.
-
BioMarin Pharmaceutical Inc. Same sectorvia Jean Jacques Bienaime
-
Evaxion A/S American Depositary Share Same sectorvia Lars Holtug
-
Immunome Inc. Same sectorvia Jean Jacques Bienaime
-
Incyte Corp. Same sectorvia Jean Jacques Bienaime
-
Keros Therapeutics Inc. Same sectorvia Jean Jacques Bienaime
-
Mirum Pharmaceuticals Inc. Same sectorvia William Fairey
-
Rein Therapeutics Inc. Same sectorvia William Fairey
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $777,068
- 9 purchases by 2 insiders
- Sold, last 12 months
- $5,513,920
- 3 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads Officer (SVP & PAO) | Option exercise | +3,000 | $110.00 | $330,000 |
| Sep 8, 2026 | Bodenhoff Mads Officer (SVP & PAO) | Open-market sale | −3,000 | $270.19 | $810,570 |
| Sep 2, 2026 | Lars Holtug Director | Open-market sale | −236 | $264.13 | $62,335 |
| Aug 14, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +1,100 | $245.85 | $270,435 |
| Aug 14, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +900 | $246.91 | $222,219 |
| Jun 2, 2026 | SMITH SCOTT THOMAS Officer (EVP & Chief Financial Officer) | Open-market purchase | +100 | $219.00 | $21,900 |
| May 29, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +200 | $223.76 | $44,752 |
| May 29, 2026 | SMITH SCOTT THOMAS Officer (EVP & Chief Financial Officer) | Open-market purchase | +250 | $223.32 | $55,830 |
| May 29, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +200 | $222.30 | $44,460 |
| May 29, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +100 | $223.50 | $22,350 |
| May 26, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +200 | $236.24 | $47,248 |
| May 26, 2026 | Jean Jacques Bienaime Director | Open-market purchase | +200 | $239.37 | $47,874 |
| May 11, 2026 | JENSEN FLEMMING STEEN Officer (See Remarks) | Open-market sale | −19,460 | $238.49 | $4,641,015 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Ascendis Pharma A/S
How many directors are on Ascendis Pharma A/S's board?
Ascendis Pharma A/S's board has 7 directors: Albert Cha, Jan Moller Mikkelsen, Jean Jacques Bienaime, Lars Holtug, Lisa Morrison, Siham Imani and William Fairey.
Are Ascendis Pharma A/S insiders buying or selling shares?
Over the last 12 months, Ascendis Pharma A/S insiders bought $777,068 of shares in 9 purchases and sold $5.5 million of shares in 3 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="ascendis-pharma-as"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.